Abstract
In the last decade, understanding of the basic pathophysiologic mechanism underlying the development of sepsis and septic shock has made impressive progress. New discoveries have challenged previously accepted concepts of infection and sepsis, and profound revisions and new therapies have been proposed. This scientific revolution led to the implementation of several large clinical trials employing new agents aimed at preventing or blocking the release of mediators involved in the development of the systemic inflammatory response characteristic of sepsis and related disorders, ultimately leading to Multiple Organ Dysfunction Syndrome (MODS). Unfortunately, the overall results indicate that these novel approaches have not been associated with a substantially improved outcome of septic patients, and in many cases both the design and the results of these trials have been criticized [1].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bernard GR (1995) Sepsis trials. Am J Resp Crit Care Med 102:4–10
Members of the American College of Chest Physician/Society of Critical Care Medicine Consensus Committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–890
Vincent JL, Bihari D (1992) Sepsis, severe sepsis or sepsis syndrome: need for clarification. Intens Care Med 18:255–257
Vincent JL (1997) Dear SIRS, I’m sorry to say I that I don’t like you… Crit Care Med 25: 372–374
Bone RC, Grodzin CJ, Balk RA (1997) Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112:235–243
Pittet D, Rangel-Frausto M, Li N et al (1995) Systemic inflammatory response, sepsis, severe sepsis and septic shock: incidence morbidities and outcomes in ICU patients. Intens Care Med 21:32–309
Rangel-Frausto M, Pittet D, Costigan M et al (1995) The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 273:117–123
Salvo I, de Cian W, Musicco M et al (1995) The Italian SEPSIS study; preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intens Care Med 21:S244-S249
Rackow EC, Astiz ME (1991) Pathophysiology and treatment of septic shock. JAMA 266: 548–554
Beriot G, Vincent JL (1992) Cardiovascular effects of cytokines. Clin Intens Care 3:199–205
Davies MG, Hagen PO (1997) Systemic inflammatory response syndrome. Br J Surg 84: 920–935
Moldawer LL (1994) Biology of proinflammatory cytokines and their antagonist. Crit Care Med 22:S3-S7
Christman JW, Holden EP, Blackwell TS (1995) Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 23:955–963
Ziegler EJ, McCuchan JA, Fierer J et al (1982) Treatment of gram-bacteremia and shock with human antiserum to a mutant Escherichia coli. New Engl J Med 307:1225–1230
Lachman E, Pitsoe SB, Gaffin SL (1984) Antilypolisaccharide immunotherapy in the management of septic shock of obstetrical and gynecological origin. Lancet 1:981–983
Fomsgaard A, Baek L, Foomsgard JS et al (1988) Preliminary study in treatment of septic shock patients with antilypolisaccharide IgG from blood donors. Scand J Infect Dis 21: 697–708
Talan DA (1993) Recent developments in our understanding of sepsis: evaluation of antiendotoxin antibodies and biological response modifiers. Ann Emer Med 22:1871–1990
Greenman RL, Schein RMH, Martin MA et al (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram- sepsis. JAMA 266: 1097–1102
Ziegler EJ, McCutchan JA, Fierer J et al (1991) Treatment of Gram- bacteremia and septic shock with HA-IA human monoclonal antibody against endotoxin. A randomized, double blind, placebo controlled trial. N Engl J Med 324:429–436
Fisher CJ, Zimmerman J, Khazaeli MB et al (1990) Initial evaluation of human monoclonal anti-lipid A antibody (HA-IA) in patients with sepsis syndrome. Crit Care Med 18:1311–1315
Greenberg RN, Wilson KM, Kunz AY et al (1992) Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious Gram- sepsis. Crit Care Med 20: 730–735
Bone RC, Balk RA, Fein AM et al (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled study. Crit Care Med 23:994–1006
Cunnion RE (1992) Clinical trials of immunotherapy for sepsis. Crit Care Med 20:721–723
Silva AT, Bayston KF, Cohen J (1990) Prophylactic and therapeutic effects of a monoclonal antibody to tumour necrosis factor-alfa in experimental Gram- shock. J Inf Dis 162:421–427
Exley AR, Cohen J, Buurman WA et al (1990) Monoclonal antibody to TNF in severe septic shock. Lancet 335:1275–1277
Vincent JL, Bakker J, Marecaux G et al (1992) Administration of anti TNF antibodies improves left ventricular function in septic shock patients: results of a pilot study. Chest 101: 810–815
Dhainaut JFA, Vincent JL, Richard C et al (1995) DP 571, a humanized antibody to tumour necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 23:1461–1469
Cohen J, Carlet J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Crit Care Med 24:1431–1440
Rheinhart K, Wiegand-Lohnert C, Grimminger F et al (1996) Assessment of the safety and effectiveness of the monoclonal anti-tumour necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose ranging study. Crit Care Med 24:733–742
Granowitz EV, Santos AA, Poutsaka DD et al (1991) Production of Interieukin-1 receptor antagonist during experimental endotoxemia. Lancet 1338:1423–1424
Dinarello CA (1991) The proinflammatory cytokines Interleukin-1 and tumor necrosis factor and treatment of septic shock syndrome. J Inf Dis 163:1177–1184
Ohlsson K, Bjork P, Bergenfeldt M et al (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 343:550–552
Arend WP (1991) Interleukin 1 receptor antagonist: a new member of Interleukin 1 family. J Clin Invest 88:1445–1451
Fisher E, Maraña MA, Van Zee KJ et al (1992) Interleukin-1 receptor antagonist improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89:1551–1557
Fisher CJ, Slotman GJ, Opal SM et al (1994) Initial evaluation of human recombinant Interleukin 1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open label, placebo-controlled multicentre trial. Crit Care Med 22:12–21
Fisher CJ, Dhainaut JF, Opal SM et al (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double bhnd, placebo-controlled trial. JAMA 271:1836–1843
Knaus WA, Harrell FE, LeBreque JF et al (1996) Use of predicted risk of mortality to evaluate the effectiveness of anticytokine therapy in sepsis. Crit Care Med 24:46–56
Bazzoni F, Beutler B (1996) Seminars in Medicine at the Beth Israel Hospital, Boston: The tumour necrosis factor ligand and receptor families. New Engl J Med 34:1717–1725
Sorkine P, Setton A, Halpem P et al (1995) Soluble tumour necrosis factor receptors reduce bowel ischemia-induced lung permeability and neutrophil sequestration. Crit Care Med 23: 1377–1381
Van Zee KJ, Kohno T, Fisher E et al (1992) Tumour necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumour necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 89:4845–4849
Möhler KM, Torrance DS, Smith CA et al (1993) Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548–1561
Fisher CJ, Agosti JA, Opal SM et al (1996) Treatment of septic shock with the tumor necrosis factor recèptor:Fc fusion protein. New Engl J Med 334:1697–1702
Abraham E, Glauser MP, Butler T et al (1997) Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multi- center trial. Jama 277:1531–1538
Bone RC (1992) Phospholipids and their inhibitors: a critical evaluation of their role in the treatment of sepsis. Crit Care Med 20:884–890
Lefer A (1989) Significance of lipid mediators in shock states. Circ Shock 27:3–12
Sun X, Hsueh W (1988) Bowel necrosis induced by tumour necrosis factor in rats is mediated by platelet activating factor. J Clin Invest 81:1328–1331
Sun X, Hsueh W, Torre-Amione G (1990) Effects of in vivo priming on endotoxin induced hypotension and tissue injury: the role of PAF and tumour necrosis factor. Am J Pathol 136: 949–956
Thompson WA, Coyle S, Van Zee K et al (1994) The metabolic effects of platelet activating factor in endotoxemic man. Arch Surg 129:72–79
Dhainaut JFA, Tenaillon A, Le Tulzo Y et al (1994) Platelet-activating factor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22:1720–1728
Gomez A, Wang R, Unruh H et al (1990) Hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 73:671–785
Stein B, Pfenninger, Grunert A et al (1990) Influence of continuous haemofiltration on haemo- dynamics and central blood volume in experimental endotoxic shock. Intens Care Med 16: 494–499
Stein B, Pfenninger, Grunert A et al (1991) The consequences of continuous haemofiltration on lung mechanics and extravascular lung water in a porcine endotoxic shock model. Intens Care Med 17:293–298
Grootendorst AF, van Bommel EFH, van der Hoven B et al (1992) High volume hemofiltration improves hemodynamics of endotoxin-induced shock in the pig. J Crit Care 7:67–75
Grootendorst AF, van Bommel EFH, van der Hoven B et al (1992) High volume hemofiltration improves right ventricular function endotoxic shock in the pig. Intensive Care Med 18: 235–240
Lee PA, Matson JR, Pry or RW, Hinshaw LB (1993) Continuous arteriovenous hemofiltration therapy for staphylococcus aureus-induced septicemia in pigs. Crit Care Med 21:914–924
Natanson C, Hoffman WD, Danner RL et al (1993) Plasma exchange does not improve survival in a canine model of human septic shock. Transfusion 33:243–248
Busund R, Lindsetmo RO, Rasmussen LT et al (1991) Tumour necrosis factor and Interleukin 1 appearance in experimental Gram-septic shock: the effects of plasma exchange with albumin and plasma infusion. Arch Surg 126:591–597
Busund R, Lindsetmo RO, Balteskard L et al (1993) Repeated plasma therapy induces fatal shock in experimental septicemia. Circ Shock 40:268–275
Gotloib L, Barzilay E, Shustak A et al (1986) Hemofiltration in septic ARDS: the artificial kidney as an artificial endocrine lung. Resuscitation 13:123–132
Coraim FJ, Coraim HP, Ebermann R, Stellwag FM (1986) Acute respiratory failure after cardiac surgery: clinical experience with the application of continuous arteriovenous hemofiltration. Crit Care Med 14:714–717
Berlot G, Gullo A, Fasiolo S et al (1997) Hemodynamic effects of plasma exchange in septic patients: preliminary report. Blood Purification 15:45–53
Storck M, Hartl WH, Zimmerer E, Inthom D (1991) Comparison of pump-driven and spontaneous continuous hemofiltration in postoperative acute renal failure. Lancet 337:452–455
Barzilay E, Kessler D, Berlot G et al (1989) The use of extracorporeal supportive techniques as additional treatment for sepsis-induced MOF patients. Crit Care Med 17:634–637
Bellomo R, Tipping P, Boyce N (1993) Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 21:522–526
Heering P, Morgera S, Schmitz FJ et al (1997) Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intens Care Med 23: 288–296
Sander A, Armbruster W, Sander B et al (1997) Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF-a plasma con- centradons. Intens Care Med 23:878–884
Peetre C, Thysell H, Gmbb A et al (1988) A tumour necrosis factor binding protein is present in human biological fluids. Eur J Haematol 41:414–419
Byrick RJ, Goldstein MB, Wong PJ (1992) Increased plasma tumour necrosis factor concentration in severe rhabdomyolysis is not reduced by continuous arteriovenous hemodialysis. Crit Care Med 20:1483–1486
Nagaki M, Hughes RD, Lau JIN, Williams R (1991) Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding. Int J Artif Org 14:43–50
Bellomo R, Parkin G, Love J, Boyce N (1993) A prospective comparative study of continuous arteriovenous hemodiafiltration and continuous venovenous hemodiafiltration in critically ill patients. Am J Kidney Dis 21:400–404
Dofferhoff ASM (1991) Release of endotoxin and other mediators during the treatment of Gram- sepsis. An introduction. Rijksuniversity Groeningen 1–32
Shenep J, Flynn PM, Barrett FF et al (1988) Serial quantitation of endotoxemia and bacteremia during therapy for Gram- bacterial sepsis. J Inf Dis 157:565–568
Endo S, Inada K, Yamada Y et al (1994) Plasma endotoxin and cytokine concentration in patients with hemorrhagic shock. Crit Care Med 22:994–1001
Hoffman JN, Hartl WH, Deppish R et al (1996) Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylotoxins and cytokines in human sepsis. Intens Care Med 22:1360–1367
Schetz M, Ferdinande P, Van den Berghe G, Lauwers P (1995) Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense? Intens Care Med 21:169–176
Pinsky MR, Vincent JL, Deviere J et al (1993) Serum cytokine levels in human septic shock: relation to multiple system organ failure and mortality. Chest 103:565–575
Calandra T, Baumgartner JD, Grau GE et al (1990) Prognostic values of tumour necrosis fac- tor/cachectin, interleukin-1, interferon-alpha, and interferon gamma in the serum of patients with septic shock. J Infect Dis 161:982–987
Calandra T, Gerain J, Heumann D et al (1991) High circulating levels of interleukin-6 in patients with septic shock evolution during sepsis, prognostic value and interplay with other cytokines. Am J Med 91:23–29
Bone RC (1996) Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation. Crit Care Med 24:163–172
Galley HE, Webster NR (1996) The immuno-inflammatory cascade. Br J Anaesth 77:11–16
Cruickshank AM, Eraser WD, Burns HJ et al (1990) Response of serum IL-6 in patients undergoing elective surgery of varying severity. Chnical Science 79:161–165
Pullicino EA, Carli F, Poole S et al (1990) The relationship between the circulating concentrations of IL-6, TNF and the acute phase response to elective surgery and accidental injury. Lymphokine Res 9:231–238
Fassbender K, Pargger H, Muller W, Zimmerli W (1993) IL-6 and acute phase protein concentrations in surgical intensive care unit patients: diagnostic sign in nosocomial infection. Crit Care Med 21:1175–1180
Waage A, Aasen AO (1992) Different role of cytokine mediators in septic shock related to meningococcal disease and surgery. Immunology 127:221–230
Dandona P, Nix D, Wilson MF et al (1994) Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79:1605–1608
Assicot M, Gendrel D, Carsin H et al (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518
Nylen ES, O’Neill W, Jordan MH et al (1992). Serum procalcitonin as an index of inhalation injury in bums. Horm Met Res 24:439–442
Badia JM, Whawell SA, Scott-Coombes DM et al (1996) Peritoneal and systemic cytokine response to laparotomy. Br J Surg 83:347–348
Iscra F, Antonaglia V, Guglielmi D, Gullo A (1997) Prognostic value of IL-6, TNF and CRP in SEPSIS/SIRS patients. Int Care Med 23[Suppl 1]:75
Wildling E, Pusch F, Aichelburg A et al (1997) Procalcitonin is elevated in patients after severe injury. Int Care Med 23[Suppl 1]:62
de Werra I, Jaccard C, Corradin SB et al (1997) Cytokines, nitrite/nitrate, S TNFr, and PCT concentration: comparisons in patients with septic shock, cardiogenic shock and bacterial pneumonia. Crit Care Med 25:607–613
Baxby D, van Saene HKF, Stoutenbeek CP, Zandstra DF (1996) Selective decontamination of the digestive tract: 13 years on, what it is and what it is not. Intensive Care Med 22:699–706
van Saene HKF, Stoutenbeek CP, Zandstra DF, Fox MA (1998) Prevention of ICU infections. In: van Saene HKF, Silvestri L, de la Cai MA (eds) Infection control in the intensive care unit. Springer-Verlag Italia, Milano, pp 225–238
Silvestri L, van Saene HKF, Gullo A (1997) Selective decontamination of the digestive tract in critically ill patients: a pathogenesis-based infection control method. Care Crit 111 13: 112–117
Brun-Buisson C, Legrand P, Rauss A et al (1989) Intestinal decontamination for control of nosocomial multi-resistant Gram-negative bacilli. Ann Intern Med 110:873–881
Silvestri L (1991) Selective decontamination of the digestive tract. Is it a strategy? In: Gullo A (ed) Recent Advances in Anaesthesia, Pain, Intensive Care and Emergency, APICE, Trieste, vol 6, pp 581–595
Potgieter PD, Hammond JM (1995) Prophylactic use of the new quinolones for the prevention of nosocomial infection in the intensive care unit. Drugs 49 [Suppl 2]: 86–91
van Saene JJM, Stoutenbeek CP, van Saene HKF et al (1996) Reduction of the intestinal endotoxin pool by three different SDD regimens in human volunteers. J Endotox Res 3: 337–343
Damjanovic V, van Saene HKF (1998) The value of surveillance cultures in neonatal intensive care units. In: van Saene HKF, Silvestri L, de la Cai MA (eds) Infection control in the Intensive Care Unit. In: Infection control in the Intensive Care Unit. Springer-Verlag Italia, Milano, pp 316–238
van Saene HKF, Baxby D, Stoutenbeek CP, Zandstra DF (1993) Selective decontamination of the digestive tract (SDD). Does it improve outcome? Does it lead to resistance? In: Gullo A (ed) Recent Advances in Anaesthesia, Pain, Intensive Care and Emergency, APICE, Trieste, pp 395–405
Selective decontamination of the digestive tract trialists collaborative group (1993) Metaanalysis of randomised controlled trials of selective decontamination of the digestive tract. Br Med J 307:525–532
Heyland DK, Cook DJ, Jaeschke R et al (1994) Selective decontamination of the digestive tract: an overview. Chest 105:1221–1229
Liberati A, D’Amico R, Pifferi S et al (1997) Antibiotic prophylaxis in adult patients treated in Intensive Care Units. The Cochrane Library, issue n 3. Abstract available from: http:// http://www.hcn.net.au/cochrane/abstracts/abOOOOOO.htm
Unertl KE, Lenhart F-P, Holzel C, Ruckdeschel G (1992) Selective digestive decontamination in ICU patients. Clinical results in trauma and general ICU patients. Rean Urg 1[3 bis]: 516–520
Hurley JC (1995) Prophylaxis with enteral antibiotics in ventilated patients: selective decontamination or selective cross-infection? Antimicrob Agents Chemother 39:941–947
Tetteroo GWM, Wagenvoort JHT, Mulder PGH et al (1993) Decreased mortality rate and length of hospital stay in surgical intensive care unit patients with successful selective decontamination of the gut. Crit Care Med 21:1692–1698
Bion JF, Badger I, Crosby HA et al (1994) Selective decontamination of the digestive tract reduces Gram-negative pulmonary colonization but not systemic endotoxaemia in patients undergoing elective liver transplantation. Crit Care Med 22:40–49
Schardey HM, Joosten U, Finke U et al (1997) The prevention of anastomotic leakage after gastrectomy with local decontamination. A prospective, randomized, double-bUnd placebo- controlled multicenter trial. Ann Surg 225:172–180
Steiberg D (1979) On leaving the peritoneal cavity open in acute generalized suppurative peritonitis. Am J Surg 137–216-220
Duff J, Moffat J (1981) Abdominal sepsis managed by leaving abdomen open. Surgery 90: 774–778
Mughal MM, Bancewicz J, Irving MH (1986) “Laparostomy”: a technique for the management of intra-abdominal sepsis. Br J Surg 73:253–259
Anderson ED, Mandelbaum DM, ElUson EC et al (1983) Open packing of the peritoneal cavity in generalized bacterial peritonitis. Am J Surg 145:131–135
Wittman DH, Aprahamian C, Bergstein JM (1990) Etappenlavage: advanced diffuse peritonitis managed by planned multiple laparotomies utilizing zippers, shde fastener, and velcro analogue for temporary abdominal closure. World J Surg 14:218–226
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Italia, Milano
About this paper
Cite this paper
Berlot, G., Silvestri, L., Iscra, F., Sganga, G., Gullo, A. (1998). Lights and Shadows in Sepsis and Multiple Organ Dysfunction Syndrome (MODS). In: Baue, A.E., Berlot, G., Gullo, A. (eds) Sepsis and Organ Dysfunction. Springer, Milano. https://doi.org/10.1007/978-88-470-2271-3_16
Download citation
DOI: https://doi.org/10.1007/978-88-470-2271-3_16
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0297-5
Online ISBN: 978-88-470-2271-3
eBook Packages: Springer Book Archive